STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Medivir (STO:MVIRB): Epiphany Biosciences announced today that the first patient was enrolled in a Phase IIb clinical trial with valomaciclovir for the treatment of herpes zoster, also known as shingles. Valomaciclovir is a highly potent anti-viral with enhanced delivery and bioavailability.
